Long term glycaemic control by alternative regimens in a feasibility study of continuous subcutaneous insulin infusion. 1986

G Knight, and A J Boulton, and J Drury, and J D Ward

Of 382 insulin-treated diabetic patients participating in a feasibility study of continuous subcutaneous insulin infusion (CSII) and alternative regimens in a large British clinic, 63 used CSII for a 2-yr period. Additionally 74 patients persisted with an intensified injection regimen and 85 continued on non-intensified therapy. There was no significant difference in mean glycosylated haemoglobin between the 3 groups at the study onset. At month 24 only the CSII group had significantly reduced mean glycosylated haemoglobin (11.0 +/- 1.8 (SD) at month 0; 9.8 +/- 1.9 month 24, p less than 0.001) although the intensified injection group experienced a significant reduction in mean glycosylated haemoglobin until month 18 (11.0 +/- 1.8 month 0; 10.1 +/- 1.4, p less than 0.001). Serious hypoglycaemia was not increased in the CSII-treated group compared with the intensified injection group. Thus it proved feasible to achieve sustained, improved glycaemic control in a large group of patients by the use of insulin pump therapy and the level of control was superior to that achieved by an intensified injection regimen.

UI MeSH Term Description Entries
D007332 Insulin Infusion Systems Portable or implantable devices for infusion of insulin. Includes open-loop systems which may be patient-operated or controlled by a pre-set program and are designed for constant delivery of small quantities of insulin, increased during food ingestion, and closed-loop systems which deliver quantities of insulin automatically based on an electronic glucose sensor. Pancreas, Artificial Endocrine,Programmable Implantable Insulin Pump,beta Cell, Artificial,Implantable Programmable Insulin Pump,Insulin Pump, Programmable Implantable,Pump, Programmable Implantable Insulin,Artificial Endocrine Pancreas,Artificial beta Cell,Artificial beta Cells,Cell, Artificial beta,Cells, Artificial beta,Endocrine Pancreas, Artificial,Infusion System, Insulin,Infusion Systems, Insulin,Insulin Infusion System,System, Insulin Infusion,Systems, Insulin Infusion,beta Cells, Artificial
D001786 Blood Glucose Glucose in blood. Blood Sugar,Glucose, Blood,Sugar, Blood
D003922 Diabetes Mellitus, Type 1 A subtype of DIABETES MELLITUS that is characterized by INSULIN deficiency. It is manifested by the sudden onset of severe HYPERGLYCEMIA, rapid progression to DIABETIC KETOACIDOSIS, and DEATH unless treated with insulin. The disease may occur at any age, but is most common in childhood or adolescence. Diabetes Mellitus, Brittle,Diabetes Mellitus, Insulin-Dependent,Diabetes Mellitus, Juvenile-Onset,Diabetes Mellitus, Ketosis-Prone,Diabetes Mellitus, Sudden-Onset,Diabetes, Autoimmune,IDDM,Autoimmune Diabetes,Diabetes Mellitus, Insulin-Dependent, 1,Diabetes Mellitus, Type I,Insulin-Dependent Diabetes Mellitus 1,Juvenile-Onset Diabetes,Type 1 Diabetes,Type 1 Diabetes Mellitus,Brittle Diabetes Mellitus,Diabetes Mellitus, Insulin Dependent,Diabetes Mellitus, Juvenile Onset,Diabetes Mellitus, Ketosis Prone,Diabetes Mellitus, Sudden Onset,Diabetes, Juvenile-Onset,Diabetes, Type 1,Insulin Dependent Diabetes Mellitus 1,Insulin-Dependent Diabetes Mellitus,Juvenile Onset Diabetes,Juvenile-Onset Diabetes Mellitus,Ketosis-Prone Diabetes Mellitus,Sudden-Onset Diabetes Mellitus
D006442 Glycated Hemoglobin Products of non-enzymatic reactions between GLUCOSE and HEMOGLOBIN (occurring as a minor fraction of the hemoglobin of ERYTHROCYTES.) It generally refers to glycated HEMOGLOBIN A. Hemoglobin A1c (Hb A1c) is hemoglobin A with GLYCATION on a terminal VALINE of the beta chain. Glycated hemoglobin A is used as an index of the average blood sugar level over a lifetime of erythrocytes. Fructated Hemoglobins,Glycohemoglobin,Glycohemoglobin A,Glycohemoglobins,Glycosylated Hemoglobin A,Hb A1c,HbA1,Hemoglobin A(1),Hemoglobin A, Glycosylated,Glycated Hemoglobin A,Glycated Hemoglobin A1c,Glycated Hemoglobins,Glycosylated Hemoglobin A1c,Hb A1,Hb A1a+b,Hb A1a-1,Hb A1a-2,Hb A1b,Hemoglobin, Glycated A1a-2,Hemoglobin, Glycated A1b,Hemoglobin, Glycosylated,Hemoglobin, Glycosylated A1a-1,Hemoglobin, Glycosylated A1b,A1a-1 Hemoglobin, Glycosylated,A1a-2 Hemoglobin, Glycated,A1b Hemoglobin, Glycated,A1b Hemoglobin, Glycosylated,Glycated A1a-2 Hemoglobin,Glycated A1b Hemoglobin,Glycosylated A1a-1 Hemoglobin,Glycosylated A1b Hemoglobin,Glycosylated Hemoglobin,Hemoglobin A, Glycated,Hemoglobin A1c, Glycated,Hemoglobin A1c, Glycosylated,Hemoglobin, Glycated,Hemoglobin, Glycated A1a 2,Hemoglobin, Glycosylated A1a 1,Hemoglobins, Fructated,Hemoglobins, Glycated
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

G Knight, and A J Boulton, and J Drury, and J D Ward
January 1986, Acta diabetologica latina,
G Knight, and A J Boulton, and J Drury, and J D Ward
October 2014, Diabetic medicine : a journal of the British Diabetic Association,
G Knight, and A J Boulton, and J Drury, and J D Ward
January 1984, The Netherlands journal of medicine,
G Knight, and A J Boulton, and J Drury, and J D Ward
July 2005, Journal of advanced nursing,
G Knight, and A J Boulton, and J Drury, and J D Ward
October 1979, Lancet (London, England),
G Knight, and A J Boulton, and J Drury, and J D Ward
April 2008, Diabetes, obesity & metabolism,
G Knight, and A J Boulton, and J Drury, and J D Ward
March 1983, Diabete & metabolisme,
G Knight, and A J Boulton, and J Drury, and J D Ward
January 1984, Diabetes care,
G Knight, and A J Boulton, and J Drury, and J D Ward
April 1981, British medical journal (Clinical research ed.),
Copied contents to your clipboard!